Edgewise Therapeutics
- Market cap
- 4.30B
- P/E (TTM)i
- -21.39
- P/Bi
- 9.59
- EPSi
- -1.63
- Div yieldi
- 0.00%
- 52W posi
- 74%
Anonymous reader poll. Unscientific, not investment advice.
About Edgewise Therapeutics
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.
- Founded
- 2017
- CEO
- Dr. Kevin Koch, PhD
- Employees
- 146
- Headquarters
- Boulder, Colorado, United States of America
- Fiscal year end
- 12-31
- Website
- edgewisetx.com
Company profile
- Exchange
- US
- Symbol
- EWTX
- Market-cap rank
- #2209
- Listing date
- 2021-03-26
- Market cap
- 4.30B
- Float cap
- 2.94B
- Shares out
- 108.60M
- Float shares
- 74.27M
Sectors & themes
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.